Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.
Be the first to review this report.
The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc. Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc. Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.
You may also be interested in
